Engineered E. coli as vehicles for targeted therapeutics

Current Gene Therapy

Volumn 10, Issue 1, 2010, Pages 27-33

  Buttaro, Caitlin ^a   Fruehauf, Johannes H ^a,b  

^a ViThera Laboratories   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Attenuation; Bacterial delivery; DapA; FDA; Gene transfer; Invasin; Listeriolysin; RNAi; TkRNAi; Transkingdom RNAi

Indexed keywords

BACTERIAL VECTOR; DNA VACCINE; FLUOROURACIL;

BACTERIAL STRAIN; CLINICAL TRIAL; DRUG TARGETING; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA INTERFERENCE;

BACTERIA (MICROORGANISMS);

EID: 77950844021     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310790945593     Document Type: Review

References (68)

1. Palffy R, Gardlik R, Hodosy J, et al. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 2006; 13(2): 101-105
2. Perez-Luz S, Abdulrazzak H, Grillot-Courvalin C, Huxley C. Factor VIII mRNA expression from a BAC carrying the intact locus made by homologous recombination. Genomics 2007; 90(5): 610-619
3. Fajac I, Grosse S, Collomber JM, et al. Recombinant Escherichia coli as a gene delivery vector into airway epithelial cells. J Control Release 2004; 97(2): 371-381
4. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005; 6(4): 299-310.
5. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which Vector for which strategy? Curr Gene Ther 2008; 8(2): 66-78.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3): 255-256
7. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118(9): 3132-3142
8. Castagliuolo I, Beggiao E, Brun P, et al. Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther 2005; 12(13): 1070-1078
9. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med 2000. 6(1): 6.
10. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270(5234): 299-302.
11. Darji A, Guzman CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91(6):765-775
12. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol 1999; 92(1): 76-89.
13. Weiss S, Krusch S. Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells. Biol Chem 2001;382(4): 533-541 (Pubitemid 32472166)
14. Grillot-Courvalin C, Goussard S, Courvalin P. Bacteria as gene delivery vectors for mammalian cells. Curr Opin Biotechnol 1999; 10(5): 477-481
15. Grillot-Courvalin C, Goussard S, Huetz F, Ojicius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 1998; 16(9): 862-866
16. Isberg RR, Barnes P. Subversion of integrins by enteropathogenic Yersinia. J Cell Sci 2001; 114(Pt 1): 21-28.
17. Conte MP, Longhi C, Buonfiglio V, Polidoro M, Seganti L, Valenti P. The effect of iron on the invasiveness of Escherichia coli carrying the inv gene of Yersinia pseudotuberculosis. J Med Microbiol 1994; 40(4): 236-240
18. Clark MA, Hirst BH, Jepson MA. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 1998; 66(3): 1237-1243
19. Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001;2(11): 1004-1009
20. Critchley-Thorne RJ, Stagg AJ, Vassaux G. Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. Mol Ther 2006; 14(2): 183-191
21. Jones J, Sugiyama M, Watt FM, Speight PM. Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J Pathol 1993; 169(2): 235-243
22. Alberti-Segui C, Goeden KR, Higgins DE. Differential function of Listeria monocytogenes listeriolysin O and phospholipases C in vacuolar dissolution following cell-to-cell spread. Cell Microbiol 2007; 9(1): 179-195
23. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL, Jr, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1(4): 233-238
24. Radford KJ, Higgins DE, Pasquini S, et al. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther 2002; 9(21):1455-1463
25. Murray P, Rosenthal KS, Pfaller MA. Bacterial attenuation. medical microbiology 2002. 3rd ed. St. Louis: Mosby 2005.
26. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006; 208(2): 290-298
27. Portnoy DA, Tweten RK, Kehoe M, Bielecki J. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect Immun 1992; 60(7): 2710-2717
28. Jeljaszewicz J, Wadstrom, Eds. Bacterial Toxins and Cell Membranes. Maryland Heights: Academic Press 1978.
29. Carrero JA, Calderon B, Vivanco-Cid H, Unanue ER. Recombinant Listeria monocytogenes expressing a cell wall-associated listeriolysin O is weakly virulent but immunogenic. Infect Immun 2009; 77(10): 4371-4382
30. Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int J Med Microbiol 2004; 294(5): 319-335
31. Bessler WG, Kleine B, Martinez AC, et al. Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunomodulators. Lung 1990;168(Suppl): 707-715
32. Loessner H, Weiss S. Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin Biol Ther 2004; 4(2): 157-168
33. Harms JS, Durward MA, Magnani DM, Splitter GA. Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella. J Immune Based Ther Vaccines 2009; 7: 1.
34. Shiau AL, Chu CY, Su WC, Wu CL. Vaccination with the glycoprotein D gene of pseudorabies virus delivered by nonpathogenic Escherichia coli elicits protective immune responses. Vaccine 2001; 19(23-24): 3277-3284
35. Fauci AS, Braunwald E, Kasper DL, et al. Eds. Harrison's principles of internal medicine. New York: McGraw-Hill 2008.
36. Simon BE, Leong JA. Gene transfer to fish cells by attenuated invasive Escherichia coli. Mar Biotechnol 2002 4(3): 303-309
37. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Transforming growth factor-B1 and matrix metalloproteinase-7 promoter variants induce risk for Helicobacter pylori-associated gastric precancerous lesions. DNA Cell Biol 2009; 28(6): 295-301.
38. Larsen MD, Griesenbach U, Goussard S, et al. Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther 2008; 15(6): 434-442
39. Laner A, Goussard S, Ramalho AS, et al. Bacterial transfer of large functional genomic DNA into human cells. Gene Ther 2005;12(21): 1559-1572
40. Critchley RJ, Jezzard S, Radford KJ, et al. Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther 2004; 11(15): 1224-1233
41. Berlutti F, Schippa S, Morea C, et al. Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. Biochem Cell Biol 2006; 84(3): 351-357
42. Xiang S, Fruehauf J, Li CJ. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 2006; 24(6):697-702.
43. Sleator R, Hill C, Eds. Patho-Biotechnology. Austin: Landes Biosciences 2008.
44. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494-498
45. Rossi JJ. Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 2008; 19(4): 313-317
46. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296(5567): 550-553
47. Kruhn A, Wang A, Fruehauf JH, Lage H. Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle 2009; 8(20): 3349-3354
48. Zhao HF, L'Abbe D, Jolicoeur N, et al. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2005; 2(12): 967-973
49. Levine MM, Woodward WE, Formal SB, et al. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis 1977;136(4): 577-582
50. Kotloff KL, Herrington DA, Hale TL, et al. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun 1992; 60(6):2218-2224
51. Henker J, Laass M, Blokhin BM, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007; 166(4): 311-318
52. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11(2): 372-378
53. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617-1623
54. Plassmann D, Schulte-Witte H. Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey. Med Klin 2007; 102(11): 888-892
55. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 2008;10(2): 158-167
56. Courvalin P, Goussard S, Grillot-Courvalin C. Gene transfer from bacteria to mammalian cells. C R Acad Sci III 1995; 318(12):1207-1212
57. McCoy AJ, Adams NE, Hudson AO, Gilvarg C, Leustek T, Maurelli AT. L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine. Proc Natl Acad Sci USA 2006; 103(47): 17909-17914
58. Harb OS, Abu Kwaik Y. Identification of the aspartate-beta-semialdehyde dehydrogenase gene of Legionella pneumophila and characterization of a null mutant. Infect Immun 1998; 66(5): 1898-1903
59. Burns-Keliher L, Nickerson CA, Morrow BJ, Curtiss R, 3rd. Cellspecific proteins synthesized by Salmonella typhimurium. Infect Immun 1998; 66(2): 856-861
60. Xu D, Kopecko DJ, Hu J, Zhang L, Zhao X, Gao L. Attenuated salmonella as a delivery system for siRNA-based tumor therapy. Washington, DC: U.S. Patent and Trademark Office Patent Number 4242581, 2007.
61. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 2004; 101(38): 13832-13837
62. Mann BA, Slauch JM. Transduction of low-copy number plasmids by bacteriophage P22. Genetics 1997; 146(2): 447-456
63. Jensen KK, Sharkova E, Duggan MF, et al. Bacillus subtilis transcription regulator, Spo0A, decreases alkaline phosphatase levels induced by phosphate starvation. J Bacteriol 1993; 175(12):3749-3756
64. Hertwig S, Popp A, Freytag B, Lurz R, Appel B. Generalized Transduction of Small Yersinie enterocolitica Plasmids. Appl Environ Microbiol 1999; 65(9): 3862-3866
65. Chiura HX. Novel Broad-host Range Gene Transfer Particles in Nature. Microbes Environ 2004; 19: 249-264
66. Lorenz MG, Wackernagel W. Bacterial gene transfer by natural genetic transformation in the environment. Microbiol Rev 1994;58(3): 563-602.
67. Baur B, Hanselmann K, Schlimme W, Jenni B. Genetic transformation in freshwater: Escherichia coli is able to develop natural competence. Appl Environ Microbiol 1996; 62(10): 3673-3678
68. Woegerbauer M, Jenni B, Thalhammer F, Graninger W, Burgmann H, Natural genetic transformation of clinical isolates of Escherichia coli in urine and water. Appl Environ Microbiol 2002; 68(1): 440-443